shiv Varan Singh

Dr. shiv Varan Singh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
ASAnbazhagan Subbaiyan
Anbazhagan Subbaiyan
KRKarthikeyan Ravichandran
Karthikeyan Ravichandran
SSshiv Varan Singh
shiv Varan Singh
MSMuthu Sankar
Muthu Sankar
PTPrasad Thomas
Prasad Thomas
PCPALLAB CHAUDHURI
PALLAB CHAUDHURI
In modern drug discovery, molecular docking analysis is routinely used to understand and predict the interaction between a drug molecule and a target protein from a microbe. Drugs identified in this way may inhibit the entry and replication of pathogens in host cells. The SARS-CoV-2 associated coronavirus disease, COVID-19, has become the most contagious and deadly pandemic disease in the world today. In abeyance of any specific vaccine or therapeutic against SARS-CoV-2, the burgeoning situation urges a need for effective drugs to treat the virus-infected patients. Herbal medicines have been used as natural remedies for treating various infectious diseases since ancient times. The spike (S) protein of SARS-CoV-2 is important for the attachment and pathogenesis of the virus. Therefore, this study focused on the search of useful ligands for S protein among active constituents present in common herbs that could serve as efficient remedies for COVID-19. We analysed the binding efficiency of twelve compounds present in common herbs with the S protein of SARS-CoV-2 through molecular docking analysis and also results are validated with two different docking tools. The binding efficiency of ligands was scored based on their predicted pharmacological interactions coupled with binding energy estimates. In docking analysis, compound “I” (Epigallocatechin gallate (EGCG)) was found to have the highest binding affinity with the viral S protein, followed by compounds, “F” (Curcumin),“D” (Apigenin) and “E” (Chrysophanol). The present study corroborates that compound “I” (EGCG) mostly present in the integrants of green tea, shows the highest potentiality for acting as an inhibitor of SARS-CoV-2. Further, characterization of the amino acid residues comprising the viral binding site and the nature of the hydrogen bonding involved in the ligand-receptor interaction revealed significant findings with herbal compound “I” (EGCG) binding to the S protein at eight amino acid residues. The binding sites are situated near to the amino acids which are required for virus pathogenicity. The findings of the present study need in vivo experiments to prove the utility of “I”, “F”,“D” and “E” compounds and their further use in making herb-based anti-SARS-CoV-2 product in near future. This analysis may help to create a new ethno-drug formulation for preventing or curing the COVID-19.

3 February 2020 in Veterinary World
Verified
Journal Article
Open access
STShikha Tamta
Shikha Tamta
VRVinodhkumar Obli Rajendran
Vinodhkumar Obli Rajendran
SSshiv Varan Singh
shiv Varan Singh
BPBommenahalli Siddaramiah Pruthvishree
Bommenahalli Siddaramiah Pruthvishree
RKRavichandran Karthikeyan
Ravichandran Karthikeyan
BSBhoj Raj Singh
Bhoj Raj Singh
Background and Aim: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are gradually increasing worldwide and carry a serious public threat. This study aimed to determine the antimicrobial resistance pattern of ESBL-producing E. coli isolated from fecal samples of piglets and pig farm workers. Materials and Methods: Fecal samples from <3-month-old piglets (n=156) and farm workers (n=21) were processed for the isolation of ESBL-producing E. coli in MacConkey agar added with 1 μg/mL of cefotaxime. E. coli (piglets=124; farm workers=21) were tested for ESBL production by combined disk method and ESBL E-strip test. Each of the ESBL-positive isolate was subjected to antibiotic susceptibility testing. The ESBL-producing E. coli were further processed for genotypic confirmation to CTX-M gene. Results: A total of 55 (44.4%, 55/124) and nine (42.9%, 9/21) ESBL-producing E. coli were isolated from piglets and farm workers, respectively. Antibiotic susceptibility testing of the ESBL-positive E. coli isolates from piglets and farm workers showed 100% resistance to ceftazidime, cefotaxime, cefotaxime/clavulanic acid, ceftazidime/clavulanic acid, and cefpodoxime. A proportion of 100% (55/55) and 88.9% (8/9) ESBL-positive E. coli were multidrug resistance (MDR) in piglets and farm workers, respectively. On genotypic screening of the ESBL E. coli isolated from piglets (n=55), 15 were positive for the blaCTX-M gene and of the nine ESBL E. coli from farm workers, none were positive for the blaCTX-M gene. Conclusion: Although there was no significant difference in isolation of ESBL-producing E. coli between piglets and farm workers, the ESBL-positive E. coli from piglets showed relatively higher MDR than farm workers.

30 April 2020 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
KRKarthikeyan Ravichandran
Karthikeyan Ravichandran
SASubbaiyan Anbazhagan
Subbaiyan Anbazhagan
SSshiv Varan Singh
shiv Varan Singh
HAHimani Agri
Himani Agri
RRRamkumar N. Rupner
Ramkumar N. Rupner
BSBhoj Raj Singh
Bhoj Raj Singh
Since the beginning of the New Year 2020, countries around the world are stumbling due to the coronavirus disease (COVID-19) pandemic. Better approaches of diagnostics and medical facilities have helped some countries recover early. Previous exposures to epidemics have imparted lessons to handle such a pandemic with a high level of preparedness. The World Health Organization (WHO) and national health authorities are taking great efforts via efficient and impactful interventions to contain the virus. Diagnostic tests such as reverse transcription-polymerase chain reaction are increasingly being used to confirm the diagnosis because testing biological samples for the presence of the virus is the definitive method to identify the disease, analyze the risk for transmission, and determine whether someone has been cured or not. It is also important to screen asymptomatic individuals to get the exact overview of the virus spread. Antibody detection plays a pivotal role in diagnosis; however, using it at the wrong time yields negative results and conveys dissenting opinion about the tests. Although the scaling up of testing has been significant, overall testing has been limited by the availability of diagnostics. Rapid diagnoses and discontinuation of transmission are keys to ending this pandemic. Diagnostics manufacturers are developing test kits and distributing them to different countries. Therefore, more than 500 commercial test kits for molecular- and immunoassays, most with Emergency Use Authorization, are now becoming available in the market. In this review, we discuss the importance of diagnostics, approaches of different countries toward the epidemic, global testing situation, and lessons to countries at the start of the epidemic for better preparedness.

2 December 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PCPallab Chaudhuri
Pallab Chaudhuri
Mani SaminathanMani Saminathan
Mani Saminathan
SASyed Atif Ali
Syed Atif Ali
GKGurpreet Kaur
Gurpreet Kaur
SSshiv Varan Singh
shiv Varan Singh
RSRaj K. Singh
Raj K. Singh
Vaccination of cattle and buffaloes with Brucella abortus strain 19 has been the mainstay for control of bovine brucellosis. However, vaccination with S19 suffers major drawbacks in terms of its safety and interference with serodiagnosis of clinical infection. Brucella abortus S19∆per, a perosamine synthetase wbkB gene deletion mutant, overcomes the drawbacks of the S19 vaccine strain. The present study aimed to evaluate the potential of Brucella abortus S19Δper vaccine candidate in the natural host, buffaloes. Safety of S19∆per, for animals use, was assessed in guinea pigs. Protective efficacy of vaccine was assessed in buffaloes by immunizing with normal dose (4 × 1010 colony forming units (CFU)/animal) and reduced dose (2 × 109 CFU/animal) of S19Δper and challenged with virulent strain of B. abortus S544 on 300 days post immunization. Bacterial persistency of S19∆per was assessed in buffalo calves after 42 days of inoculation. Different serological, biochemical and pathological studies were performed to evaluate the S19∆per vaccine. The S19Δper immunized animals showed significantly low levels of anti-lipopolysaccharides (LPS) antibodies. All the immunized animals were protected against challenge infection with B. abortus S544. Sera from the majority of S19Δper immunized buffalo calves showed moderate to weak agglutination to RBPT antigen and thereby, could apparently be differentiated from S19 vaccinated and clinically-infected animals. The S19Δper was more sensitive to buffalo serum complement mediated lysis than its parent strain, S19. Animals culled at 6-weeks-post vaccination showed no gross lesions in organs and there was comparatively lower burden of infection in the lymph nodes of S19Δper immunized animals. With attributes of higher safety, strong protective efficacy and potential of differentiating infected from vaccinated animals (DIVA), S19Δper would be a prospective alternate to conventional S19 vaccines for control of bovine brucellosis as proven in buffaloes.

23 April 2020 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
BSBhoj R. Singh
Bhoj R. Singh
RGRicha Gandharva
Richa Gandharva
RKR. Karthikeyan
R. Karthikeyan
SSshiv Varan Singh
shiv Varan Singh
AYAkanksha Yadav
Akanksha Yadav
SGSumedha Gandharava
Sumedha Gandharava

20 June 2023 in Microbiology Resource Announcements
Verified
Journal Article
Open access
AYAkanksha Yadav
Akanksha Yadav
BSBhoj Raj Singh
Bhoj Raj Singh
APAbhijit M. Pawde
Abhijit M. Pawde
PTPrasad Thomas
Prasad Thomas
VSVidya Singh
Vidya Singh
Raghavendra AmachawadiRaghavendra Amachawadi
Raghavendra Amachawadi
Here, we report the genome sequence of a Pasteurella multocida strain isolated from the heart blood of a spotted deer (Bareilly, India). The 2.44-Mbp genome has 2,227 coding sequences, with a G+C content of 40.7%.